论文部分内容阅读
目的:观察痰热清注射液联合舒利迭治疗慢性阻塞性肺疾病的疗效。方法:将97例慢性阻塞性肺疾病患者随机分为两组,治疗组49例,对照组例48例,2组均采用舒利迭(沙美特罗替卡松粉吸入剂)治疗;治疗组加用痰热清注射液治疗。观察两组患者治疗前后动脉血气变化、肺功能、生活质量评分情况。结果:治疗组在治疗后4周的Pa O2、Pa CO2及p H分别为(78.2±8.5)mm Hg、(47.8±8.4)mm Hg、(7.38±0.06),对照组分别为(63.5±9.0)mm Hg、(57.6±9.5)mm Hg、(7.26±0.07),经t检验,组间差异均有统计学意义(P<0.05);治疗组在治疗后4周的FEV1、FEV1/FVC分别为(1.95±0.60)L、(65.58±7.95);对照组分别为(1.71±0.65)L、(57.50±7.80),经t检验,组间差异均有统计学意义(P<0.05);治疗组在治疗后4周的生活质量得分为(12.82±3.86)分,对照组为(19.72±4.29)分,经t检验,组间差异均有统计学意义(P<0.05)。结论:痰热清注射液联合舒利迭可以显著改善慢性阻塞性肺疾病患者肺功能,提高患者生存质量。
Objective: To observe the curative effect of Tanreqing injection combined with seretide on chronic obstructive pulmonary disease. Methods: Ninety-seven patients with chronic obstructive pulmonary disease were randomly divided into two groups: 49 cases in the treatment group and 48 cases in the control group. Both groups were treated with seretide (salmeterramide TX powder inhalation) Plus Tanreqing injection treatment. The changes of arterial blood gas, lung function and quality of life before and after treatment in both groups were observed. Results: Pa O2, Pa CO2 and p H were (78.2 ± 8.5) mm Hg, (47.8 ± 8.4) mm Hg and (7.38 ± 0.06), respectively, in the control group at 4 weeks after treatment ), Hg (57.6 ± 9.5) mm Hg and (7.26 ± 0.07) respectively. There was significant difference between the two groups (P <0.05) by t test. The FEV1 and FEV1 / FVC of the treatment group after 4 weeks (1.95 ± 0.60) L and (65.58 ± 7.95), respectively; the control group was (1.71 ± 0.65) L, (57.50 ± 7.80) respectively. There was significant difference between the two groups (P <0.05) The quality of life score of the 4 weeks after treatment was (12.82 ± 3.86) points in the control group and (19.72 ± 4.29) points in the control group. There was significant difference between the two groups (P <0.05) by t test. Conclusion: Tanreqing injection combined with seretide can significantly improve pulmonary function in patients with chronic obstructive pulmonary disease and improve the quality of life of patients.